Myasthenia Gravis Disease Market Research Report - Forecast to 2023

Myasthenia Gravis Disease Market Research Report - Forecast to 2023

ID: MRFR/HC/4387-HCRR | November, 2018 | Region: Global | 100 pages | Half-Cooked Research Reports

Global Myasthenia Gravis Disease Market Research Report: Diagnosis (Imaging, Blood Tests, Electrodiagnostic, Edrophonium Test), Treatment (Medication, Surgery, HSCT), End-User (Hospitals, Clinics, Academic Research Institutes) – Global Forecast Till 2023


Market Scenario


Myasthenia gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body. This condition occurs due to the impairment of communication between muscles and nerve cells. This impairment causes difficulties in the contraction and relaxation of muscles which are crucial for carrying out daily activities, resulting in muscle weakness. It mostly affects the muscles that control the eyes and eyelids, facial expressions, chewing, and speaking. As per a study conducted by the Myasthenia Gravis Foundation of America, myasthenia gravis is the most common type of neuromuscular disorder. It is a rare condition with a prevalence of 14 to 20 cases per 100,000 people in the United States.


Numerous organizations are undertaking global initiatives and spreading awareness about this disease. Some of these are as follows: Myasthenia Gravis Foundation of America, Inc., American Autoimmune Related Diseases Association, Muscular Dystrophy Association, and others.


The prognosis of the patients of myasthenia gravis is usually good and the quality of treatment can subside the disease if treated at early stages.


This condition can occur both in males and females and all ethnic groups. It usually affects women under 40 and the geriatric population from 50 to 70 years old. Younger patients are rarely diagnosed with the myasthenia gravis disease also known as thymus tumor (thymoma). According to the National Institute of Neurological Disorders and Stroke (NINDS) about 60,000 Americans suffer from neuromuscular disorders each year in the U.S.


Factors such as increasing cases of neuromuscular disorders, growing awareness regarding the treatment line, and increasing number of clinical facilities across the region are driving the market growth. However, the high cost of treatment and ignorance of signs and symptoms are constraining the growth of the market.


The global market for the myasthenia gravis disease is expected to grow at a CAGR of approximately 7.5% during 2017 to 2023.


Research Methodology


 Myasthenia Gravis Disease Market Methodology


Sources: Annual reports, Press release, White paper, and Company presentation Intended Audience



  • Myasthenia gravis drug manufacturers

  • Myasthenia gravis drug suppliers

  • Biotechnology companies

  • Government institutes

  • Research and development companies

  • Academic medical centers and universities

  • Research and consulting firms

  • Venture capital firms


Figure 1: - Global Myasthenia Gravis Disease Market Share, by Region


 Myasthenia Gravis Disease Market Share


Segmentation


The global myasthenia gravis disease market has been segmented on the basis of diagnosis, treatment, and end-user.


On the basis of diagnosis, the global myasthenia gravis disease market can be segmented into imaging, blood tests, electrodiagnostic, edrophonium tests, pulmonary function tests, and others. The imaging segment is classified into X-ray, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and others.


On the basis of treatment, the global myasthenia gravis disease market can be segmented into medication, surgery, autologous Hematopoietic Stem Cell Transplantation (HSCT), plasmapheresis and intravenous immunoglobulin, and others.


The medication segment is divided into acetylcholinesterase inhibitors, immunosuppressant drugs, steroids, and others. The acetylcholinesterase inhibitors are classified into atropine, neostigmine, pyridostigmine, and others. The immunosuppressant drugs are further divided into azathioprine, mycophenolate mofetil, tacrolimus, and rituximab. The steroids are further divided into prednisone, and others. Surgery is finally divided into thymectomy and others.


On the basis of end-user, the global myasthenia gravis disease market is segmented into hospitals, clinics, academic research institutes, and others.


Regional Analysis                     


The global myasthenia gravis disease market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.


The Americas accounted for the largest market share of the global myasthenia gravis disease market owing to the growing number of drug manufacturers, increasing awareness about the long-term effects of muscle dystrophy, and rising government funding for the treatment of this disease in the region. Moreover, the U.S. contributes to a significant market share in the global pharmaceutical industry.


The European myasthenia gravis disease market is the second largest market followed by the Asia Pacific region.


The Asia Pacific region is expected to emerge as the fastest growing market for the global myasthenia gravis disease market due to the growing awareness about neuromuscular disorders and vast improvement in health care reforms in countries such as Malaysia, India, Indonesia, and China.


The Middle Eastern region is expected to grow at a steady pace owing to factors such as the extensive development of the healthcare infrastructure and rising R&D activities in the healthcare sector.


Key Players


Some of the key players in the global myasthenia gravis disease market are Valeant Pharmaceuticals International (U.S.), Sun Pharmaceuticals Industries Ltd. (India), Piramal Healthcare (India), Novartis Pharmaceuticals Corporation (Switzerland), Apotex Corporation (Canada), Teva Pharmaceutical Industries Ltd. (Israel), RPG Life Sciences (India), Cipla (India), F. Hoffmann Roche La Ltd. (Switzerland), Bristol-Myers Squibb Company (U.S.), Biogen Inc. (U.S.), and AbbVie Inc. (U.S.), GlaxoSmithKline plc (UK), Fresenius Kabi (Germany), and others

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Myasthenia Gravis Disease Market, by Diagnosis

6.1 Introduction

6.2 Imaging

6.2.1 Market Estimates & Forecast, 2017–2023

6.2.2 X-ray

6.2.2.1 Market Estimates & Forecast, 2017–2023

6.2.3 Computed Tomography (CT)

6.2.3.1 Market Estimates & Forecast, 2017–2023

6.2.3 Magnetic Resonance Imaging (MRI)

6.2.3.1 Market Estimates & Forecast, 2017–2023

6.2.3 Others

6.3 Blood Tests

6.3.1 Market Estimates & Forecast, 2017–2023

6.4 Electrodiagnostic

6.4.1 Market Estimates & Forecast, 2017–2023

6.5 Edrophonium Test

6.5.1 Market Estimates & Forecast, 2017–2023

6.6 Pulmonary Function Test

6.6.1 Market Estimates & Forecast, 2017–2023

6.7 Others

Chapter 7. Global Myasthenia Gravis Disease Market, by Treatment

7.1 Introduction

7.2 Medication

7.2.1 Market Estimates & Forecast, 2017–2023

7.2.2 Acetylcholinesterase Inhibitors

7.2.2.1 Market Estimates & Forecast, 2017–2023

7.2.2.2 Atropine

7.2.2.2.1 Market Estimates & Forecast, 2017–2023

7.2.2.3 Neostigmine

7.2.2.3.1 Market Estimates & Forecast, 2017–2023

7.2.2.4 Pyridostigmine.

7.2.2.4.1 Market Estimates & Forecast, 2017–2023

7.2.2.4 Others

7.2.3 Immunosuppressant Drugs

7.2.3.1 Market Estimates & Forecast, 2017–2023

7.2.3.2 Rituximab

7.2.3.2.1 Market Estimates & Forecast, 2017–2023

7.2.3.3 Azathioprine

7.2.3.3.1 Market Estimates & Forecast, 2017–2023

7.2.3.4 Mycophenolate Mofetil

7.2.3.4.1 Market Estimates & Forecast, 2017–2023

7.2.3.5 Tacrolimus.

7.2.3.5.1 Market Estimates & Forecast, 2017–2023

7.2.3.6 Others

7.2.4 Steroid

7.2.4.1 Market Estimates & Forecast, 2017–2023

7.2.4.2 Prednisone

7.2.4.2.1 Market Estimates & Forecast, 2017–2023

7.2.4.3 Others

7.2.5 Others

7.3 Surgery

7.3.1 Market Estimates & Forecast, 2017–2023

7.2.4 Thymectomy

7.2.4.1 Market Estimates & Forecast, 2017–2023

7.2.4 Others

7.4 Autologous. Hematopoietic Stem Cell Transplantation (HSCT)

7.4.1 Market Estimates & Forecast, 2017–2023

7.5 Plasmapheresis and Intravenous. Immunoglobulin

7.5.1 Market Estimates & Forecast, 2017–2023

7.6 Others

Chapter 8. Global Myasthenia Gravis Disease Market, by End-User

8.1 Introduction

8.2 Hospitals

8.2.1 Market Estimates & Forecast, 2017–2023

8.3 Clinics

8.3.1 Market Estimates & Forecast, 2017–2023

8.4 Academic Research Institutes

8.4.1 Market Estimates & Forecast, 2017–2023

8.4 Others

Chapter .9 Global Myasthenia Gravis Disease Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 U.S.

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 U.K.

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Valeant Pharmaceuticals International

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Sun Pharmaceuticals Industries Ltd

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Novartis Pharmaceuticals Corporation

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Teva Pharmaceutical Industries Ltd.

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Cipla Limited

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 F. Hoffmann Roche La Ltd.

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 Apotex Corporation

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Pfizer Inc.

11.8.1 Company Overview

11.8.2 Product/Business Segment Overview

11.8.3 Financial Overview

11.8.4 Key Development

11.8.5 SWOT Analysis

11.9 Bristol-Myers and Company

11.9.1 Company Overview

11.9.2 Product Overview

11.9.3 Financial overview

11.9.4 Key Developments

11.10 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of the Pharmaceutical Industry

Chapter 13 Appendix



LIST OF TABLES

Table 1 Myasthenia Gravis Disease Industry Synopsis, 2017–2023

Table 2 Myasthenia Gravis Disease Market Estimates & Forecast, 2017–2023, (USD Million)

Table 3 Myasthenia Gravis Disease Market, by Region, 2017–2023, (USD Million)

Table 4 Myasthenia Gravis Disease Market, by Diagnosis, 2017–2023, (USD Million)

Table 5 Myasthenia Gravis Disease Market, by Treatment, 2017–2023, (USD Million)

Table 6 Myasthenia Gravis Disease Market, by End-User, 2017–2023, (USD Million)

Table 7 North America myasthenia Gravis Disease Market, by Diagnosis, 2017–2023, (USD Million)

Table 8 North America Myasthenia Gravis Disease Market, by Treatment, 2017–2023, (USD Million)

Table 9 North America Myasthenia Gravis Disease Market, by End-User, 2017–2023, (USD Million)

Table 10 U.S. Myasthenia Gravis Disease Market, by Diagnosis, 2017–2023, (USD Million)

Table 11 U.S. Myasthenia Gravis Disease Market, by Treatment, 2017–2023, (USD Million)

Table 12 U.S. Myasthenia Gravis Disease Market, by End-User, 2017–2023, (USD Million)

Table 13 Canada Myasthenia Gravis Disease Market, by Diagnosis, 2017–2023, (USD Million)

Table 14 Canada Myasthenia Gravis Disease Market, by Treatment, 2017–2023, (USD Million)

Table 15 Canada Myasthenia Gravis Disease Market, by End-User, 2017–2023, (USD Million)

Table 16 South America Myasthenia Gravis Disease Market, by Diagnosis, 2017–2023, (USD Million)

Table 17 South America Myasthenia Gravis Disease Market, by Treatment, 2017–2023, (USD Million)

Table 18 South America Myasthenia Gravis Disease Market, by End-User, 2017–2023, (USD Million)

Table 19 Europe Myasthenia Gravis Disease Market, by Diagnosis, 2017–2023, (USD Million)

Table 20 Europe Myasthenia Gravis Disease Market, by Treatment, 2017–2023, (USD Million)

Table 21 Europe Myasthenia Gravis Disease Market, by End-User, 2017–2023, (USD Million)

Table 22 Western Europe Myasthenia Gravis Disease Market, by Diagnosis, 2017–2023, (USD Million)

Table 23 Western Europe Myasthenia Gravis Disease Market, by Treatment, 2017–2023, (USD Million)

Table 24 Western Europe Myasthenia Gravis Disease Market, by End-User, 2017–2023, (USD Million)

Table 25 Eastern Europe Myasthenia Gravis Disease Market, by Diagnosis, 2017–2023, (USD Million)

Table 26 Eastern Europe Myasthenia Gravis Disease Market, by Treatment, 2017–2023, (USD Million)

Table 27 Eastern Europe Myasthenia Gravis Disease Market, by End-User, 2017–2023, (USD Million)

Table 28 Asia Pacific Myasthenia Gravis Disease Market, by Diagnosis, 2017–2023, (USD Million)

Table 29 Asia Pacific Myasthenia Gravis Disease Market, by Treatment, 2017–2023, (USD Million)

Table 30 Asia Pacific Myasthenia Gravis Disease Market, by End-User, 2017–2023, (USD Million)

Table 31 Middle East & Africa Myasthenia Gravis Disease Market, by Diagnosis, 2017–2023, (USD Million)

Table 32 Middle East & Africa Myasthenia Gravis Disease Market, by Treatment, 2017–2023, (USD Million)

Table 33 Middle East & Africa Myasthenia Gravis Disease Market, by End-User, 2017–2023, (USD Million)



LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for the Myasthenia Gravis Disease Market

Figure 3 Segmentation Market Dynamics for the Myasthenia Gravis Disease Market

Figure 4 Global Myasthenia Gravis Disease Market Share, by Diagnosis 2016

Figure 5 Global Myasthenia Gravis Disease Market Share, by Treatment 2016

Figure 6 Global Myasthenia Gravis Disease Market Share, by End-User, 2016

Figure 7 Global Myasthenia Gravis Disease Market Share, by Region, 2016

Figure 8 North America Myasthenia Gravis Disease Market Share, by Country, 2016

Figure 9 Europe Myasthenia Gravis Disease Market Share, by Country, 2016

Figure 10 Asia Pacific Myasthenia Gravis Disease Market Share, by Country, 2016

Figure 11 Middle East & Africa Myasthenia Gravis Disease Market Share, by Country, 2016

Figure 12 Global Myasthenia Gravis Disease Market: Company Share Analysis, 2016 (%)

Figure 13 Valeant Pharmaceuticals International: Key Financials

Figure 14 Valeant Pharmaceuticals International: Segmental Revenue

Figure 15 Valeant Pharmaceuticals International: Geographical Revenue

Figure 16 Sun Pharmaceuticals Industries Ltd: Key Financials

Figure 17 Sun Pharmaceuticals Industries Ltd: Segmental Revenue

Figure 18 Sun Pharmaceuticals Industries Ltd: Geographical Revenue

Figure 19 Novartis Pharmaceuticals Corporation: Key Financials

Figure 20 Novartis Pharmaceuticals Corporation: Segmental Revenue

Figure 21 Novartis Pharmaceuticals Corporation: Geographical Revenue

Figure 22 Circle Cardiovascular Imaging Inc: Key Financials

Figure 23 Circle Cardiovascular Imaging Inc: Segmental Revenue

Figure 24 Circle Cardiovascular Imaging Inc: Geographical Revenue

Figure 25 Cipla Limited: Key Financials

Figure 26 Cipla Limited: Segmental Revenue

Figure 27 Cipla Limited: Geographical Revenue

Figure 28 F. Hoffmann Roche La Ltd.: Key Financials

Figure 29 F. Hoffmann Roche La Ltd.: Segmental Revenue

Figure 30 F. Hoffmann Roche La Ltd.: Geographical Revenue

Figure 31 Apotex Corporation: Key Financials

Figure 32 Apotex Corporation: Segmental Revenue

Figure 33 Apotex Corporation: Geographical Revenue

Figure 34 Pfizer Inc.: Key Financials

Figure 35 Pfizer Inc.: Segmental Revenue

Figure 36 Pfizer Inc.: Geographical Revenue

Figure 37 Bristol-Myers and Company: Key Financials

Figure 38 Bristol-Myers and Company: Segmental Revenue

Figure 39 Bristol-Myers and Company: Geographical Revenue